Macedon, Victoria

Cell and Gene Therapy CDMO Andelyn Biosciences Celebrates Over 20 Years of Leadership and Innovation with Opening of New 180,000 Square Foot Manufacturing Headquarters

Retrieved on: 
Thursday, June 22, 2023
Research, Venture Capital, Professional Services, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, ACC, Clinical trial, Macedon, Victoria, Multimedia, DSM-IV codes, AAV, CGMP, Quality control, ADC, Growth, APC, We Are One: The Obama Inaugural Celebration at the Lincoln Memorial, Hospital, Nationwide, Safety, Innovation district, Vaccine

Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.

Key Points: 
  • Andelyn Biosciences, a pioneer in the development and manufacturing of cell and gene therapies, today formally inaugurates its new manufacturing headquarters, the Andelyn Corporate Center (ACC), located in the Innovation District in Columbus, Ohio.
  • With 180,000 square feet of office, laboratory, and manufacturing space, the ACC more than triples Andelyn’s footprint, ensuring the company will have the space and capabilities to meet the growing demand for its cell and gene therapy services.
  • View the full release here: https://www.businesswire.com/news/home/20230622541586/en/
    Wade Macedone, Chief Executive Officer of Andelyn Biosciences, commented, “The opening of the new Andelyn Corporate Center is a fitting tribute to our more than 20 years of leadership and innovation in the development and manufacture of viral vectors for gene therapy.
  • The company also supports the development and manufacturing of other viral vector processes and cell-based gene therapies.

FDA Accepts GMP Plasmid DMF and Capacity Expansion Enabling Andelyn Biosciences to Offer Faster Gene Therapy Development

Retrieved on: 
Thursday, January 13, 2022
Vaccination, Macedon, Victoria, Patient, Research, BLA, CDMO, COVID-19, COO, Growth, IND, DNA, Plasmid, GMP, Industry, Efficiency, Hospital, Ohio State University College of Medicine, Therapy, Nationwide Children's Hospital, FDA, API, Solution, RNA transfection, University, DMF, Vaccine, Fine chemical, Innovation district

With industry capacity restrictions and throughput bottlenecks, gene therapy manufacturers wait, on average, ten months for production, analytical analysis, and release of plasmids.

Key Points: 
  • With industry capacity restrictions and throughput bottlenecks, gene therapy manufacturers wait, on average, ten months for production, analytical analysis, and release of plasmids.
  • This wait, combined with delays associated with fragmented materials suppliers and CDMOs, often results in a gene therapy commercial manufacturing timeline of approximately 18 months.
  • While the GMP plasmid DNA offering is key to vertically integrating the complete gene therapy manufacturing process for Andelyn's clients, increased production capacity is another factor.
  • Capacity expansions coupled with our clinical-grade plasmid DNA offering allows us to be a fully vertically integrated gene therapy CDMO continuing to contribute to the capacity and capabilities required to advance the gene therapy sector."